B of A Securities Rates ACADIA Pharmaceuticals (ACAD) buy

B of A Securities Keeps Buy Rating on ACADIA Pharmaceuticals

On June 30, 2026, B of A Securities analyst Tazeen Ahmad reaffirmed a buy rating on ACADIA Pharmaceuticals Inc. (NasdaqGS: ACAD) alongside a $30.00 price target. The update keeps the firm aligned with a positive stance on the biotechnology company as shares navigate the middle of their yearly trading range.

Stock Price Levels and Analyst Targets

Shares recently changed hands at $25.48, placing the stock well below the $30.00 target set by B of A Securities and under the broader Wall Street consensus. Across 19 analyst opinions, the stock holds a consensus buy recommendation with a mean price target of $33.89, stretching from a high of $49.00 down to $17.00. The equity has moved between a 52-week low of $19.69 and a 52-week high of $30.96.

Recent Analyst Updates Across Wall Street

Wall Street firms have actively adjusted their outlooks on the biotech firm through the autumn months. On October 13, 2026, UBS lowered its stance to a neutral rating and dropped its target to $23.00 from $49.00. Earlier in the month on October 8, 2026, RBC Capital kept an outperform rating while trimming its target from $37.00 to $36.00. Back on September 25, 2026, Deutsche Bank maintained a buy rating while adjusting its target to $31.00 from $38.00. On that same day, HC Wainwright & Co. kept its buy rating with a target moved down to $33.00 from $37.00, Citizens maintained a market outperform rating with a target of $33.00 down from $36.00, BMO Capital kept an outperform rating with a target of $34.00 down from $36.00, and Needham kept a buy rating with a target of $35.00 down from $41.00. Citigroup also contributed on September 24, 2026, maintaining a buy rating while moving its target from $40.00 to $33.00.

Financial Health and Valuation Metrics

ACADIA Pharmaceuticals Inc. operates with a market capitalization of roughly $4.55 billion and a trailing price-to-earnings ratio of 11.84. The biotech firm posted $1.14 billion in revenue over the trailing period, reflecting a revenue growth rate of 16.4%. Profitability metrics show a net margin of 33.4% and a return on equity of 35.7%, supported by a current ratio of 3.39 and a debt-to-equity ratio of 5.65.

Inside the Business Operations

Headquartered in San Diego, California, ACADIA Pharmaceuticals is a biopharmaceutical company focused on developing and selling treatments for neurological and rare conditions in North America. Its product portfolio features NUPLAZID for hallucinations and delusions linked to Parkinson's disease psychosis, alongside DAYBUE for treating Rett syndrome symptoms. The enterprise also runs clinical pipelines addressing Alzheimer's disease psychosis, major depressive disorder, and other central nervous system disorders.

What to Watch at ACADIA Pharmaceuticals Inc.

Investors are tracking upcoming corporate updates, with the company's next earnings report scheduled for November 4, 2026. Market participants will monitor pipeline trial progress and quarterly revenue figures to see if results justify current analyst targets.